Primary Immunodeficiency Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented By Disease Type (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Others), By Product Type and Geography.

Market Snapshot

primary immunodeficiency therapeutics market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.1 %
 primary immunodeficiency therapeutics market size

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Primary Immunodeficiency Therapeutics Market is expected to register a CAGR of 6.1% during the forecast period. Primary immunodeficiencies are a group of different disorders in which part of the body's immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.

Treatment options for primary immunodeficiency diseases are targeted towards specific immune defects and can include transplantation bone marrow transplantation, stem cell transplantation, immunoglobulin replacement therapy, antibiotic therapy and strategies to manage primary immunodeficiency diseases. Gene therapy has been successful in specific types of primary immunodeficiency disease. Research in primary immunodeficiency disease treatment is making great strides, advance treatment options and improving the quality of life for most people with these complex conditions.

According to the National Institute of Allergy and Infectious Diseases, estimates more than 200 different forms of primary immune deficiency diseases affecting approximately 500,000 people in the United States and these rare genetic diseases may be debilitating, chronic, and costly. Furthermore, as per the California Institute for Regenerative Medicine, severe combined immunodeficiency (SCID) is a rare genetic disorder, affecting one in 30,000 newborns.

Rising incidences of immune diseases in children and technological advancements in gene therapy are the key driving factors in the primary immunodeficiency therapeutics market.

Scope of the Report

Primary immunodeficiencies are group of different disorders in which part of the body's immune system (mainly cells and proteins) is missing or does not function normally. Primary Immunodeficiency Therapeutics Market is segmented By Disease Type, Product Type and Geography.

By Disease Type
Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disorders
By Product Type
Immunoglobulin Replacement Therapy
Stem Cell/Bone Marrow Transplantation
Antibiotic Therapy
Gene Therapy
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Gene Therapy Segment is Expected to Hold a Major Market Share in the Primary Immunodeficiency Therapeutics Market

Most primary immunodeficiencies are genetic disorders. Gene therapy represents a life-saving alternative for those patients with severe forms of primary immunodeficiency diseases. Till now, gene therapy has been used to treat some of the primary immunodeficiencies diseases such as X-linked SCID, SCID secondary to adenosine deaminase (ADA) deficiency, CGD and WAS. According to the Immune Deficiency Foundation, common variable immune deficiency (CVID) is a relatively frequent form of primary immunodeficiency, affecting about 1 in 25,000 persons. Moreover, about 20% of patients have symptoms of the common variable immune deficiency (CVID) disease or are found to be immunodeficient in childhood because the immune system matures slow, and the diagnosis of CVID is generally not made until after the age of 4 years.

Gene therapy segment holds a significant market share in the primary immunodeficiency therapeutics market and is anticipated to show a similar trend over the forecast period due to the promising results of recent clinical trials, it is likely that gene therapies will become standard of care for a number of devastating diseases in the coming years.

Rising incidences of immune diseases in children and technological advancements in gene therapy are the key driving factors in the gene therapy segment.

primary immunodeficiency therapeutics market share

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global primary immunodeficiency therapeutics market due to rising prevalence of immunodeficiency diseases and technological advancements in genetic and stem cell therapy in this region. According to the Centers for Disease Control and Prevention, in the United States, babies born with severe combined immunodeficiency die before 1 year of age without medical treatment because immune system cannot fight against infection. Furthermore, increasing healthcare expenditure and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

primary immunodeficiency therapeutics industry

Competitive Landscape

The Primary Immunodeficiency Therapeutics Market is Consolidated competitive and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Baxter international Inc, Takeda Pharmaceutical Company Limited, CSL Ltd, Biotest AG, Octapharma AG, Kedrion Biopharma Inc, Bio Products Laboratory Limited, LFB group, Grifols S.A and Lupin Pharmaceuticals.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Immunodeficiency diseases

      2. 4.2.2 Technological Advancements in Genetic Therapy

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of the Therapies

      2. 4.3.2 Side Effects Associated with the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Disease Type

      1. 5.1.1 Antibody Deficiency

      2. 5.1.2 Cellular Immunodeficiency

      3. 5.1.3 Innate Immune Disorders

      4. 5.1.4 Others

    2. 5.2 By Product Type

      1. 5.2.1 Immunoglobulin Replacement Therapy

      2. 5.2.2 Stem Cell/Bone Marrow Transplantation

      3. 5.2.3 Antibiotic Therapy

      4. 5.2.4 Gene Therapy

      5. 5.2.5 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Baxter international Inc

      2. 6.1.2 Takeda Pharmaceutical Company Limited

      3. 6.1.3 CSL Ltd

      4. 6.1.4 Octapharma AG

      5. 6.1.5 Biotest AG

      6. 6.1.6 Kedrion Biopharma Inc

      7. 6.1.7 Bio Products Laboratory Limited

      8. 6.1.8 LFB group

      9. 6.1.9 Grifols S.A

      10. 6.1.10 Lupin Pharmaceuticals

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Primary Immunodeficiency Therapeutics Market market is studied from 2018 - 2026.

The Primary Immunodeficiency Therapeutics Market is growing at a CAGR of 6.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Baxter international Inc, Takeda Pharmaceutical Company Limited, CSL Ltd, Octapharma AG, Biotest AG are the major companies operating in Primary Immunodeficiency Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!